The Phase 3 SUSTAIN OPTIMIZE study (NCT05514535) investigating semaglutide in combination with a lower dose of insulin glargine for people with Type 2 Diabetes and Obesity completed its primary phase on 2025-03-05. This trial enrolled 568 participants to compare this regimen against a higher dose of insulin glargine alone.
Background
Semaglutide is a medication currently used in the management of Type 2 Diabetes and Obesity. The SUSTAIN OPTIMIZE study further explores its potential role, specifically in combination with insulin glargine, for managing blood glucose levels in this patient population.
Trial design
The SUSTAIN OPTIMIZE study (NCT05514535) is a Phase 3 trial that enrolled 568 participants. The study focused on individuals diagnosed with Type 2 Diabetes and Obesity. Participants were assigned to one of two intervention arms: either semaglutide together with a lower dose of insulin glargine U100, or a higher, titrated dose of insulin glargine U100 alone. The trial aimed to evaluate how well these study medicines control blood glucose levels over approximately 47 weeks.
What this means
The primary completion of the SUSTAIN OPTIMIZE trial marks a significant step towards understanding the comparative efficacy of semaglutide in combination with a lower dose of insulin glargine versus a higher dose of insulin glargine alone for managing Type 2 Diabetes and Obesity. Clinicians and researchers will await the detailed results to assess the potential benefits of this combination therapy in controlling blood glucose levels.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05514535, titled "A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)," was updated with the primary completion date of 2025-03-05 on clinicaltrials.gov.